#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Leber's congenital amaurosis Factor IX deficiency Congenital growth hormone deficiency Medullary thyroid cancer Systemic lupus erythematosus Alexander disease Antithrombin III deficiency Albright's disease Congenital generalised lipodystrophy Synovial sarcoma Craniocerebral injury Optic ischaemic neuropathy Congenital leptin deficiency Oesophageal squamous cell carcinoma Advanced systemic mastocytosis More trials…

    Learn about Rare Diseases

    Ehlers-Danlos syndrome – Trials in Disease Ewing’s sarcoma – Life with Disease Paraneoplastic neurological syndrome – Diagnostics Splenic marginal zone lymphoma – Diagnostics VEXAS syndrome – Basic Information Breast angiosarcoma – Basic Information Hypereosinophilic syndrome – Trials in Disease Bronchopulmonary dysplasia – Treatment Hereditary optic atrophy – Basic Information Waldenstrom’s macroglobulinaemia recurrent – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gallium (68Ga) Chloride Gad20-209-Fsp-A1 Fluindione Neflamapimod Tezepelumab Inotuzumab Ozogamicin Emicizumab Spironolactone Camphor Resamirigene Bilparvovec Ruxotemitide Procarbazine Natalizumab Bupivacaine Aspergillus Fumigatus L-Tyrosine Wt1/Il15/Il15Ra Mrna Dc ATOVAQUONE ANTIMETABOLITES NORGESTIMATE More therapies…

    Learn about Your Condition

    Post-traumatic headache Hyperparathyroidism primary Thalassaemia beta Peritoneal neoplasm Autoimmune hepatitis Adrenocortical carcinoma Neuralgia Status epilepticus Asplenia Atopic keratoconjunctivitis Lumbosacral radiculopathy Apathy Complex regional pain syndrome Blood disorder Propionic acidaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hippokration Hospital

Hippokration Hospital

Vassilissas Sofias Avenue 114, Athens, 115 27, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Enpatoran in Adults with Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE)

    Not recruiting

    2 1
    Investigated Diseases:
    • Chronic cutaneous lupus erythematosus
    • Cutaneous lupus erythematosus
    • Subacute cutaneous lupus erythematosus
    Investigated Drugs:
    • Enpatoran
    Bulgaria Greece Poland Romania Spain

  • Study on the Safety and Effectiveness of Giroctocogene Fitelparvovec for Adult Men with Moderate to Severe Hemophilia A

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Factor VIII deficiency
    Investigated Drugs:
    • Giroctocogene Fitelparvovec
    France Germany Greece Spain Sweden

  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    3 1
    Investigated Drugs:
    • Risankizumab
    Austria Belgium Bulgaria Croatia Czechia France +13

  • Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Atorvastatin
    • Inclisiran
    • Rosuvastatin
    Austria Belgium Bulgaria Croatia Czechia Denmark +18

  • Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

    Not recruiting

    3 1 1
    Investigated Diseases:
    • IgA nephropathy
    Investigated Drugs:
    • Ravulizumab
    Austria Belgium Czechia France Germany Greece +6

  • Study on the Long-term Safety and Effectiveness of Danicopan with Ravulizumab or Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Paroxysmal nocturnal haemoglobinuria
    Investigated Drugs:
    • Danicopan
    • Eculizumab
    • Ravulizumab
    Czechia France Greece Italy Poland Spain

  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Ianalumab
    Bulgaria France Germany Greece Hungary Italy +5

  • Study on the Effects of Etavopivat for Patients Aged 12-65 with Sickle Cell Disease

    Not recruiting

    4 1
    Investigated Diseases:
    • Sickle cell disease
    Investigated Drugs:
    • Etavopivat
    France Germany Greece Italy Spain

  • Study on Sibeprenlimab for Patients with IgA Nephropathy

    Not recruiting

    3 1
    Investigated Diseases:
    • IgA nephropathy
    Investigated Drugs:
    • Sibeprenlimab
    Belgium Croatia Czechia France Germany Greece +6

  • Study on the Effects of Enpatoran for Patients with Dermatomyositis and Polymyositis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Dermatomyositis
    • Polymyositis
    Investigated Drugs:
    • Enpatoran
    Czechia Greece Italy Poland Spain Sweden
Previous Page
1 … 9 10 11 12 13 14
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!